{"id":"ivacaftor-exposed","safety":{"commonSideEffects":[{"rate":"10%","effect":"Nausea"},{"rate":"5%","effect":"Vomiting"},{"rate":"5%","effect":"Diarrhea"},{"rate":"5%","effect":"Headache"},{"rate":"5%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2010601","moleculeType":"Small molecule","molecularWeight":"392.50"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that works by increasing the amount of chloride ions that are secreted through the CFTR protein, which helps to thin mucus and improve lung function.","oneSentence":"Potentiates CFTR chloride channel function","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:57:10.406Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis"}]},"trialDetails":[{"nctId":"NCT04618185","phase":"","title":"Gut Imaging for Function & Transit in CF - GIFT-CF 3","status":"COMPLETED","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2020-10-21","conditions":"Cystic Fibrosis","enrollment":24},{"nctId":"NCT06302270","phase":"","title":"CFTR Modulators in Pregnancy and Postpartum","status":"RECRUITING","sponsor":"Region Stockholm","startDate":"2024-03-15","conditions":"Cystic Fibrosis","enrollment":75},{"nctId":"NCT04056702","phase":"","title":"Impact of Triple Combination CFTR Therapy on Sinus Disease.","status":"UNKNOWN","sponsor":"Jennifer Taylor-Cousar","startDate":"2019-09-05","conditions":"Cystic Fibrosis","enrollment":31},{"nctId":"NCT02722057","phase":"","title":"A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-12","conditions":"Cystic Fibrosis","enrollment":368},{"nctId":"NCT01863238","phase":"","title":"An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-05","conditions":"Cystic Fibrosis","enrollment":95}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":49,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Ivacaftor Exposed","genericName":"Ivacaftor Exposed","companyName":"Vertex Pharmaceuticals Incorporated","companyId":"vertex-pharmaceuticals-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ivacaftor is a small molecule that acts as a positive modulator of the cystic fibrosis transmembrane conductance regulator. It is used to treat cystic fibrosis, as indicated by clinical trials registered on ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}